Mode
Text Size
Log in / Sign up

Hypoxia coordinates cancer stem cell phenotypes with immune-related mechanisms and therapeutic resistance in cancerHypoxia Linked to Cancer Stem Cells and Immune Suppression

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that hypoxia coordinates cancer stem cell phenotypes and immune suppression, though evidence is currently experimental.

This systematic review synthesized 14 studies from 39 reports to evaluate how hypoxia or hypoxia-associated signaling coordinates cancer stem cell (CSC) phenotypes with immune-related mechanisms. The review identifies that hypoxia-associated conditions are linked to CSC enrichment, self-renewal, epithelial-to-mesenchymal transition, tumorigenicity, metastatic potential, immune suppression, and therapeutic resistance.

Key findings indicate that hypoxia impairs the function of natural killer cells, cytokine-induced killer cells, and CD8-positive T-cells. Furthermore, myeloid and macrophage-mediated effects reinforce CSC states through polarization, cytokine signaling, extracellular vesicles, cellular transfer, and stromal or vascular remodeling. The review also identifies checkpoint-associated and adaptive immune suppression involving PD-L1, CD47, regulatory T cells, and myeloid-derived suppressor cells.

The authors note that the evidence is predominantly experimental and the hypoxic CSC-immune niche is a mechanistic framework rather than a confirmed universal pathway. While preclinical intervention studies suggest that specific pathways may be therapeutically modifiable, the current evidence is not sufficient to establish a universal clinical pathway. Clinical application is currently limited by the experimental nature of the data.

How this fits prior evidence

This systematic review addresses a gap in the understanding of the tumor microenvironment's role in cancer progression. While prior coverage has focused on supportive care, such as psychosocial interventions for children with cancer, early palliative care, and nutrition-oriented perioperative nursing, this review focuses on the underlying biological mechanisms of hypoxia and its role in promoting cancer stem cell phenotypes and immune evasion.

This review looked at how low oxygen levels, known as hypoxia, affect cancer stem cells and the immune system. Researchers analyzed 14 studies to see how these conditions influence how cancer grows and spreads. The findings suggest that hypoxia is linked to several factors, including the growth of cancer stem cells, their ability to self-renew, and their potential to spread to other parts of the body.

In addition to helping cancer cells grow, these conditions were linked to the suppression of immune cells. Specifically, the study found that certain immune cells, such as natural killer cells and T-cells, had their functions impaired. The research also noted that hypoxia can involve immune checkpoints and other signals that help the cancer evade the body's natural defenses.

It is important to note that most of this evidence comes from laboratory and experimental settings. The researchers noted that this is a framework for understanding how cancer behaves rather than a proven universal pathway. While some pathways might be targets for future treatments, the findings are currently experimental and not yet used in standard clinical practice.

What this means for you:
Low oxygen in tumors may help cancer stem cells grow while weakening the immune system's response.

Common questions

What is the role of hypoxia in cancer?

Hypoxia refers to low oxygen levels in the tissue. This review found that these conditions are linked to the enrichment of cancer stem cells, their ability to self-renew, and their potential to spread. It also appears to contribute to immune suppression, making it harder for the body to fight the cancer.

How does low oxygen affect the immune system's response?

The study found that hypoxia-associated conditions can impair the function of natural killer cells, cytokine-induced killer cells, and CD8-positive T-cells. It also involves immune checkpoints like PD-L1 and CD47, which can help the cancer evade the immune system's defenses.

Is this finding a proven way to treat cancer?

No, the evidence is currently mostly experimental and based on laboratory models. While some pathways identified in the study might be targets for future treatments, the findings are a mechanistic framework rather than a proven universal pathway for clinical use.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedSep 2026
View Original Abstract ↓
BackgroundHypoxia, cancer stem cell (CSC) plasticity, and immune suppression are established features of the tumor microenvironment, but their integration within the same biological systems has not been comprehensively synthesized. This systematic review evaluated whether hypoxia or hypoxia-associated signaling coordinates CSC or stemness phenotypes with immune-related mechanisms.MethodsPubMed, Embase, Scopus, Web of Science, and Google Scholar were searched for English-language studies published from 1 January 2010 to 31 January 2026. Eligible studies were required to evaluate hypoxia or hypoxia-associated signaling, CSC or stemness phenotypes, and immune-related outcomes within the same experimental or translational study. Of 1,569 records identified, 39 reports underwent full-text assessment and 14 studies were included.ResultsHypoxia-associated conditions were recurrently linked to CSC enrichment, self-renewal, epithelial-to-mesenchymal transition, tumorigenicity, metastatic potential, immune suppression, and therapeutic resistance. Four context-dependent patterns emerged: impaired natural killer, cytokine-induced killer, and CD8-positive T-cell function; myeloid- and macrophage-mediated reinforcement of CSC states through polarization, cytokine signaling, extracellular vesicles, cellular transfer, and stromal or vascular remodeling; checkpoint-associated and adaptive immune suppression involving PD-L1, CD47, regulatory T cells, and myeloid-derived suppressor cells; and an integrated hypoxic CSC–immune niche phenotype. Preclinical intervention studies indicated that selected pathways may be therapeutically modifiable, although the evidence remained predominantly experimental.ConclusionsHypoxia appears to act as a coordinating microenvironmental pressure linking CSC plasticity with immune dysfunction in selected tumor contexts. The proposed hypoxic CSC–immune niche is a mechanistic framework rather than evidence of a universal pathway and requires validation using spatially resolved human tumors, patient-derived immune models, and treatment-response-linked cohorts.Systematic review registrationhttps://www.crd.york.ac.uk/PROSPERO/view/CRD420261287704, identifier CRD420261287704.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.